Benzinga
20 May 2026, 18:22 UTC · 18w ago
Verdict
Headline takes no side. We score PSNL +1.00 across three claims — strongly bullish.
+1.00strongly bullish
More positive than 98% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
CMS has expanded Medicare coverage for Personalis' NeXT Personal test to include breast cancer patients undergoing neoadjuvant therapy.
More positive than 99% of claims this week
The new coverage applies specifically to patients with Stage II-III triple-negative and HER2-positive breast cancer.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 77% of claims this week
Personalis shares rose 9.30% following the announcement of the coverage expansion.
More positive than 51% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
The company received expanded Medicare coverage for its NeXT Personal breast cancer test, leading to a significant share price increase.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
11h ago
+132.2%
Price agrees with the score
$16.35 vs $7.04 close before publication (May 19) · not market-adjusted
PSNL chart →
